Ekso Bionics

Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Bionics, Nasdaq, SAN, Ekso Bionics, Paralysis, GLOBE, Conference, Company, Twitter, Industry, San Francisco Bay Area

SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Key Points: 
  • SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
  • Ekso Bionicsis a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
  • The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Reports Second Quarter 2022 Results

Retrieved on: 
Thursday, July 28, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Awareness, Nasdaq, Bionics, Industry, Food, Multiple sclerosis, Twitter, Research, Forward-looking statement, SEC, Marketing, Webcast, MS, FDA, Company, Patient, Annual report, Paralysis, Ekso Bionics, Growth, Mobile phone, Renewable energy, Online gambling, Video game, Lithium, Aquaculture, San Francisco Bay Area

RICHMOND, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2022.

Key Points: 
  • RICHMOND, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2022.
  • Revenue was $3.5 million for the quarter ended June 30, 2022 compared to $2.2 million for the same period in 2021.
  • Revenue in the second quarter of 2022 included approximately $3.2 million in EksoHealth revenue and approximately $0.2 million in EksoWorks revenue.
  • The Company booked a total of 17 EksoNR units in the second quarter of 2022.

United States Human Augmentation Markets, 2022-2027 - Growing Implementation of Human Augmentation Technologies in Industrial Applications - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 21, 2022
Technology, Health, Other Technology, Telemedicine, Virtual Medicine, Magic Leap, Product type, Investment, Fossil Group, Defense, COVID-19, Casio, Market development, Science and technology in Asia, Consumer, Industry, Commercial, Risk, USD, Ansoff Matrix, CAGR, Emotion, Competitive analysis, Impact, Ekso Bionics, Google, Growth, Real estate, Retail, Risk management, Function, Application, Industrial

The US Human Augmentation Market is estimated to be USD 29.3 Bn in 2022 and is projected to reach USD 77.1 Bn by 2027, growing at a CAGR of 21.35%.

Key Points: 
  • The US Human Augmentation Market is estimated to be USD 29.3 Bn in 2022 and is projected to reach USD 77.1 Bn by 2027, growing at a CAGR of 21.35%.
  • Market dynamics are forces that impact the prices and behaviors of the US Human Augmentation Market stakeholders.
  • These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.
  • The report presents a detailed Ansoff matrix analysis for the US Human Augmentation Market.

Ekso Bionics to Report Second Quarter 2022 Financial Results on July 28

Retrieved on: 
Thursday, July 21, 2022
Nasdaq, Bionics, Paralysis, GLOBE, Ekso Bionics, Company, Industry, Twitter, Mobile phone, San Francisco Bay Area

RICHMOND, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2022 after the close of trading on Thursday, July 28, 2022.

Key Points: 
  • RICHMOND, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2022 after the close of trading on Thursday, July 28, 2022.
  • ET to discuss the financial results and recent business developments.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications.
  • The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Retrieved on: 
Monday, June 13, 2022
Company, Paralysis, Stroke, Bionics, Fatigue, Ekso Bionics, Food, Central nervous system, Rancho Los Amigos National Rehabilitation Center, Forward-looking statement, Brain, Neurodegeneration, Nasdaq, Severe cognitive impairment, FDA, ABI, GLOBE, Patient, MS, Technology, COVID-19, Multiple sclerosis, Rehabilitation, SEC, Twitter, Industry, Hypoesthesia, National, Regulation of tobacco by the U.S. Food and Drug Administration, Medical device, San Francisco Bay Area

RICHMOND, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR™ robotic exoskeleton for use with Multiple Sclerosis (MS) patients. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication which significantly expands the device’s use to a broader group of patients.

Key Points: 
  • RICHMOND, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR robotic exoskeleton for use with Multiple Sclerosis (MS) patients.
  • EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication which significantly expands the devices use to a broader group of patients.
  • EksoNR is the latest-generation device of the most clinically used robotic exoskeleton on the market.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer

Retrieved on: 
Thursday, May 26, 2022
Company, Ekso Bionics, Nasdaq, University, Paralysis, COVID-19, ABM Industries, Industry, University of British Columbia, Bionics, Forward-looking statement, Twitter, SEC, CFO, Growth, Interim, Controller, GLOBE, Pharmaceutical industry, Risk management, San Francisco Bay Area

RICHMOND, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn.

Key Points: 
  • RICHMOND, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn.
  • I am excited that Jerome has accepted the Interim CFO role after having served as our Controller for the past five years, said Scott Davis, President and Chief Operating Officer of Ekso Bionics.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or refer to the Companys Twitter page at @EksoBionics.

Ekso Bionics to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022
Industry, Company, Twitter, Nasdaq, Conference, Bionics, Paralysis, Ekso Bionics, GLOBE, San Francisco Bay Area

RICHMOND, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022.

Key Points: 
  • RICHMOND, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Reports First Quarter 2022 Results

Retrieved on: 
Thursday, April 28, 2022
EVO, Twitter, Nasdaq, GLOBE, Research, Forward-looking statement, Growth, Traction, Company, Mission statement, Ekso Bionics, Marketing, Webcast, Industry, SEC, Paralysis, Bionics, Safety, Online gambling, Cryptocurrency, Video game, San Francisco Bay Area

RICHMOND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2022.

Key Points: 
  • RICHMOND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2022.
  • Revenue was $2.6 million for the quarter ended March 31, 2022, compared to $1.9 million for the same period in 2021.
  • Revenue in the first quarter of 2022 included approximately $1.9 million in EksoHealth revenue and approximately $0.7 million in EksoWorks sales.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics to Report First Quarter 2022 Financial Results on April 28

Retrieved on: 
Thursday, April 21, 2022
Bionics, Industry, Company, Nasdaq, Paralysis, GLOBE, Ekso Bionics, Twitter, Mobile phone, San Francisco Bay Area

RICHMOND, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2022 after the close of trading on Thursday, April 28, 2022.

Key Points: 
  • RICHMOND, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2022 after the close of trading on Thursday, April 28, 2022.
  • ET to discuss the financial results and recent business developments.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Reports Fourth Quarter and Year End 2021 Results

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Webcast, Twitter, Growth, Bionics, Overalls, Awareness, Research, Nasdaq, COVID-19, Industry, Company, Paralysis, EVO, Forward-looking statement, Patient, Marketing, Mission statement, Ekso Bionics, SEC, Mobile phone, Online gambling, Video game, Animal, Lithium, San Francisco Bay Area

Strong cash position at December 31, 2021 of $40.4 million

Key Points: 
  • Strong cash position at December 31, 2021 of $40.4 million
    As a company that is elevating the care of neurorehabilitation, Ekso Bionics is bringing innovative solutions to patients and workers, said Steven Sherman, Chairman and Chief Executive Officer of Ekso Bionics.
  • Revenue was $4.1 million for the quarter ended December 31, 2021, compared to $2.3 million for the same period in 2020.
  • Revenue in the fourth quarter of 2021 included approximately $3.4 million in EksoHealth revenue and approximately $0.6 million in EksoWorks revenue.
  • The Company booked a total of 30 EksoNR units in the fourth quarter of 2021, including 10 subscription units.